Authors
Tatsuro Saito
Published in
Gan to kagaku ryoho. Cancer & chemotherapy. Volume 53. Issue 11. Pages 697-702.
Abstract
Companion diagnostics (CDx) are in vitro diagnostics (IVD) or medical devices (MD) used to identify patients who are expected to benefit from, or avoid safety risks associated with, a specific therapeutic product based on biomarker results. In precision oncology, the clinical value of molecularly targeted therapy depends on accurate patient selection using appropriately validated assays. This review summarizes the regulatory and reimbursement landscape for CDx and related genetic testing in Japan, with selected comparisons to the United States. The article outlines the definition of CDx, the distinction between primary and follow-on CDx, cross-drug CDx, and major product configurations, including IVD products, MD programs, and combination MD systems. Key development considerations include coordination with drug development, use of clinical trial assays, bridging to the final CDx, sample availability, and strategies for rare biomarkers. The review also discusses US features such as FDA oversight of companion diagnostics, group labeling, laboratory developed tests, and payer coverage pathways. Finally, it examines Japanese reimbursement categories for CDx, multi-gene tests, comprehensive genomic profiling, and the gap between test costs and reimbursement when CGP includes CDx functions. These differences indicate that successful CDx development requires not only analytical and clinical validation, but also early planning for labeling, laboratory workflow, payer coverage, reimbursement level, and sustainable access in routine oncology practice.
PMID:
43039369
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0